Adcetris (brentuximab vedotin)

pCPA File Number: 21371

Negotiation Status:

Concluded with an LOI

Indication(s):

Primary Cutaneous Anaplastic Large Cell Lymphoma (or CD30- Expressing Mycosis Fungoides)

Sponsor/Manufacturer:

Seattle Genetics Inc.

CDA-AMC Project Number:

PC0213-000

pCPA Engagement Letter Issued:

2021-02-05

Negotiation Process Concluded:

2021-04-28